Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. It offers farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021.

Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its second-quarter 2021 financial results.

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021.

Metacrine to Present at 2021 Canaccord Genuity Growth Conference

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data at the European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.

Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organisation (ECCO) 2021 Virtual Congress

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021. Data to be presented includes results from the Company's Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), as well as one oral presentation and one poster focused on preclinical studies examining FXR agonists in rare adult and pediatric cholestatic liver diseases.

Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET409 in combination with empagliflozin (Jardiance®), a sodium-glucose cotransport-2 (SGLT2) inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The Company plans to report topline data in the fourth quarter of 2021.

Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Jefferies Healthcare Conference at 11:00 a.m. ET on Friday, June 4, 2021.

Metacrine to Present at 2021 Jefferies Healthcare Conference

Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD

Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting

SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it has enrolled the first 60 patients in its MET642 Phase 2a trial. The Company remains on track to report interim results in the fourth quarter of 2021 after these patients have completed 16 weeks of treatment.

Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 RBC Global Healthcare Conference at 5:25 p.m. ET on Tuesday, May 18, 2021.

Metacrine to Present at 2021 RBC Global Healthcare Conference

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company's board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.

Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021

Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

American Well Corporation

Athira Pharma

Broadstone Net Lease

COMPASS Pathways

Coupang

Dyne Therapeutics

GreenBox POS

908 Devices

Outset Medical

Poshmark

Pactiv Evergreen

StepStone Group

Sumo Logic

Vitru Limited

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week

Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results and other business highlights on Thursday, March 18, 2021 at 8:30 a.m. ET.

Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

On-track for Interim Analysis Readout in the Fourth Quarter of 2021 On-track for Interim Analysis Readout in the Fourth Quarter of 2021

Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the H.C. Wainwright 2021 Global Life Sciences Conference, being held March 9-10, 2021.

Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 4:20 p.m. ET.

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

ARCA biopharma

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value. Should the company fail, these shareholders would, in theory, still be able to make money due to a difference between the liquidation value and purchasing price.

3 Net-Net Working Capital Stocks

Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET642, the company's second farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).

Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs

Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase

Metacrine Reports Positive Results from Phase 1 Trial of MET642

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences:

Metacrine to Participate in Upcoming Investor Conferences

Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH

News for Metacrine Stock (MTCR)